DE69740038D1 - - Google Patents

Info

Publication number
DE69740038D1
DE69740038D1 DE69740038T DE69740038T DE69740038D1 DE 69740038 D1 DE69740038 D1 DE 69740038D1 DE 69740038 T DE69740038 T DE 69740038T DE 69740038 T DE69740038 T DE 69740038T DE 69740038 D1 DE69740038 D1 DE 69740038D1
Authority
DE
Germany
Prior art keywords
adhesins
chimeric
heteromultimeric
erbb2
heteromultimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69740038T
Other languages
German (de)
English (en)
Inventor
Vincent Danial Fizpatrick
Mark Sliwkowski
Richard L Vandlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69740038D1 publication Critical patent/DE69740038D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
DE69740038T 1996-07-12 1997-07-08 Expired - Lifetime DE69740038D1 (US20040106767A1-20040603-C00005.png)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2164096P 1996-07-12 1996-07-12
US79832697A 1997-02-10 1997-02-10
PCT/US1997/011825 WO1998002540A1 (en) 1996-07-12 1997-07-08 Chimeric heteromultimer adhesins

Publications (1)

Publication Number Publication Date
DE69740038D1 true DE69740038D1 (US20040106767A1-20040603-C00005.png) 2010-12-16

Family

ID=26694954

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69740038T Expired - Lifetime DE69740038D1 (US20040106767A1-20040603-C00005.png) 1996-07-12 1997-07-08

Country Status (13)

Country Link
US (3) US6696290B2 (US20040106767A1-20040603-C00005.png)
EP (2) EP0938556B1 (US20040106767A1-20040603-C00005.png)
JP (2) JP4274581B2 (US20040106767A1-20040603-C00005.png)
CN (1) CN1202247C (US20040106767A1-20040603-C00005.png)
AT (1) ATE486937T1 (US20040106767A1-20040603-C00005.png)
AU (1) AU722178B2 (US20040106767A1-20040603-C00005.png)
BR (1) BR9710357A (US20040106767A1-20040603-C00005.png)
CA (1) CA2258721C (US20040106767A1-20040603-C00005.png)
DE (1) DE69740038D1 (US20040106767A1-20040603-C00005.png)
DK (1) DK0912734T3 (US20040106767A1-20040603-C00005.png)
IL (1) IL127891A0 (US20040106767A1-20040603-C00005.png)
NZ (1) NZ333325A (US20040106767A1-20040603-C00005.png)
WO (1) WO1998002540A1 (US20040106767A1-20040603-C00005.png)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455283B1 (en) * 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
ES2381650T3 (es) 2000-08-08 2012-05-30 Zymogenetics, Inc. Receptores de citoquinas Zcytor11 solubles
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
ATE427317T1 (de) * 2001-07-31 2009-04-15 Univ Wayne State Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
WO2003080835A1 (en) * 2002-03-26 2003-10-02 Zensun (Shanghai) Sci-Tech. Ltd. Erbb3 based methods and compositions for treating neoplasms
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
ATE517914T1 (de) * 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
DE602005022475D1 (de) 2004-10-22 2010-09-02 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
EP2298815B1 (en) * 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007064882A2 (en) * 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
AU2007213709A1 (en) * 2006-02-08 2007-08-16 Targeted Molecular Diagnostics, Llc Bivalent ErbB ligand binding molecules and methods for their preparation and use
CN101611150A (zh) * 2006-02-08 2009-12-23 利佳赛普特有限责任公司 二价ErbB配体结合分子及其制备和使用方法
SG170021A1 (en) 2006-02-23 2011-04-29 Novocell Inc Compositions and methods useful for culturing differentiable cells
AU2007257683A1 (en) * 2006-06-12 2007-12-21 Symphogen A/S Pan-cell surface receptor- specific therapeutics
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
EP2035452B1 (en) * 2006-06-22 2012-04-25 Novo Nordisk A/S Soluble heterodimeric receptors and uses thereof
US20090182127A1 (en) * 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
EP2205629A2 (en) * 2007-10-16 2010-07-14 Symphogen A/S Compositions comprising optimized her1 and her3 multimers and methods of use thereof
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
EP2318548B1 (en) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US9198952B2 (en) 2008-09-22 2015-12-01 The Brigham And Women's Hospital, Inc. Compositions of and methods of using ligand dimers
KR101789338B1 (ko) 2008-11-25 2017-10-23 제넨테크, 인크. 이소형 특이적 항-ｈｅｒ４ 항체
CN102470157B (zh) * 2009-07-28 2016-08-17 里加赛谱有限公司 广谱erbb配体结合分子及其制备和使用方法
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012103114A2 (en) * 2011-01-24 2012-08-02 Jason Hill Therapeutic chimeric ligand binding proteins and methods for their use
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
WO2014051567A1 (en) * 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
WO2015003149A2 (en) * 2013-07-05 2015-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
KR20180117529A (ko) 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
WO2019132517A1 (ko) * 2017-12-26 2019-07-04 주식회사 프로티나 세포 내 또는 세포 간 단백질-단백질 상호작용 분석 방법 및 장치
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
EP1201756A3 (en) 1988-12-22 2002-10-30 Genentech, Inc. Method for preparing water soluble polypeptides
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0444961A1 (en) 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5254536A (en) * 1992-01-10 1993-10-19 The Du Pont Merck Pharmaceutical Company Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
ATE163231T1 (de) 1993-11-23 1998-02-15 Genentech Inc Kinaserezeptoraktivierungstest
US5844092A (en) * 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides

Also Published As

Publication number Publication date
EP0912734A1 (en) 1999-05-06
NZ333325A (en) 2000-06-23
CN1225129A (zh) 1999-08-04
EP0938556B1 (en) 2005-03-09
US20040138417A1 (en) 2004-07-15
AU722178B2 (en) 2000-07-27
US7659368B2 (en) 2010-02-09
EP0912734B1 (en) 2010-11-03
JP4274581B2 (ja) 2009-06-10
US20070081994A1 (en) 2007-04-12
JP2008115187A (ja) 2008-05-22
WO1998002540A1 (en) 1998-01-22
US20030199020A1 (en) 2003-10-23
CN1202247C (zh) 2005-05-18
BR9710357A (pt) 1999-08-17
US6696290B2 (en) 2004-02-24
AU3596297A (en) 1998-02-09
ATE486937T1 (de) 2010-11-15
IL127891A0 (en) 1999-10-28
JP2000515372A (ja) 2000-11-21
CA2258721C (en) 2014-09-09
DK0912734T3 (da) 2011-02-07
EP0938556A1 (en) 1999-09-01
CA2258721A1 (en) 1998-01-22

Similar Documents

Publication Publication Date Title
DE69740038D1 (US20040106767A1-20040603-C00005.png)
IL127892A0 (en) Gamma-heregulin
NZ516258A (en) Tek antagonists
PL331405A1 (en) Modified ligands of tie-2 receptor
GB9022648D0 (en) Polypeptide and its use
BG104268A (en) Bitumen or asphalt for producing road surfacing, road surfacing and method for the preparation of bitumen or asphalt
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
TW200628490A (en) Novel anti-IGF-IR antibodies and uses thereof
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
IL136728A0 (en) Novel g protein-coupled receptor
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
MX9600666A (es) Proteinas de protocadherina y su uso.
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
EP1017713A4 (en) CYCLIC AGONISTS AND ANTAGONISTS OF THE C5A RECEPTORS AND G-PROTEIN COUPLED RECEPTORS
WO1999019488A8 (en) Novel human egf receptors and use thereof
NZ329807A (en) NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
CA2171289A1 (en) Il8 inhibitors
ATE279515T1 (de) Pct-65 serotonin rezeptor
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
HK1004411A1 (en) A novel haemopoietin receptor
EP0858505A4 (en) CLONING PHEROMONIC RECEPTORS FROM VERTEBRATES AND THEIR USE
AU2003288810A1 (en) Peptides that bind to the heparin binding domian of vegf and vegfr-2
NO975565L (no) Benstimulerende faktor